Lykos Therapeutics (formerly MAPS PBC) shared groundbreaking research on the impact of MDMA-assisted therapy on emotional coping skills and self-experience in PTSD. The study’s findings could mark a pivotal moment in the quest for more effective treatments for PTSD.

An Australian study explored the potential therapeutic effects of an ayahuasca-inspired N, N-DMT and harmine formulation in healthy subjects, shedding light on the promise of novel psychedelic compounds in medical settings.

Preliminary evidence of the antidepressant effects of vaporized DMT in treatment-resistant depression emerged, hinting at the untapped potential of psychedelic compounds in mental health treatment.

The exploration of psilocybin’s cell-type-specific changes in the orbitofrontal cortex in a Chinese government-backed research has opened new pathways for understanding the neurological effects of psychedelics.

Analyzing the attitude toward LSD risk in the U.S. from 2015 to 2019 revealed increasingly favorable perceptions. The findings prompt reflection on the evolving public perception of the drug.

A comprehensive review highlighted the potential of psychedelics for acquired brain injury treatment, signaling an expanding scope of applications for psychedelic compounds in healthcare.

A study delved into the knowledge gaps in psychedelic medicalization, emphasizing the need for continued research and regulatory discourse to harness the therapeutic potential of psychedelics.

Imperial College London’s investigation into the use of psilocybin to revert brain dysfunction in gamblers opened a new frontier in the exploration of psychedelic therapy’s broad-ranging applications.

A new qualitative survey study elucidated the coping and support strategies employed by individuals to navigate extended difficulties after using psychedelic drugs, shedding light on the nuanced experiences of psychedelic therapy recipients.

The FDA’s Reagan-Udall Foundation announced an upcoming virtual public workshop titled “Advancing Psychedelic Clinical Study Design,” signaling an increased focus on refining clinical research methodologies in the psychedelic space.

A free workshop on Tripping for Partners, led by Dr. Ido Cohen and organized by DoubleBlind, presented a unique opportunity for individuals to delve into the therapeutic potential of psychedelic experiences within a supportive framework.

The year-end review of the best cannabis/drug books of 2023 offered a nuanced lens through which to explore the evolving discourse surrounding psychedelic and cannabis literature.

Insightful analyses by renowned journalists and scholars delved into the complex tapestry of psychedelics investments and their potential impact on healthcare and society, underlining the growing interest in the field.

Eminent researchers provided in-depth insights into the mechanisms behind the healing potential of psychedelics, expanding the discourse surrounding their therapeutic potential and the intricate nature of their effects.

Engaging discussions explored the philosophical underpinnings of psychedelics and the critical role of metaphysics, hinting at the profound implications of psychedelic therapy on existential and philosophical inquiries.

Insightful commentaries highlighted the need for a deeper understanding of metaphysical aspects in psychedelic therapy and research, paving the way for a more nuanced and holistic approach to psychedelic exploration.

Revealing statistics about the mental health impact of psychedelic therapy provided a comprehensive and data-driven perspective on the transformative potential of psychedelic experiences in the realm of mental well-being.